TSXV:BTI.H - Post by User
Comment by
prophetoffactzon Dec 16, 2022 2:26pm
77 Views
Post# 35176440
RE:RE:RE:RE:panobinostat, lomustine, xB3-bevacizumab
RE:RE:RE:RE:panobinostat, lomustine, xB3-bevacizumabJDavenport wrote: poofster says, "xB3 has never been in a stronger position."
That's true, I agree.
And Bioasis shareholders have never been in a weaker position.
jd
So now instead of 24,000% upside to Denali they have 1/10 of that or 2,400%. But the clinical assets BTI is being merged with may be substantially undervalued themselves and given the revenue generating potential there is a chance to limit dilution. Also, given the clinical trial infrastrucutre BTI will now have it is now positioned to advance xB3 assets themselves and enter more substantial strategic alliances on better terms. What could a cancer strategic alliance look like now given the new strength.